A study led by scientists at Victor Chang Cardiac Research Institute in Sydney, Australia, has shown that the transcription factor hypoxia-inducible factor 1 (HIF-1) suppresses harmful reactive oxygen species (ROS)-induced growth of cardiac fibroblasts (CFs) and fibrotic scarring after myocardial infarction (MI) in knockout (KO) mice.
Vuno Inc. has received its third breakthrough device designation from South Korea’s Ministry of Food and Drug Safety (MFDS), for its artificial intelligence (AI)-based electrocardiogram (ECG) analysis software Vuno Med DeepECG. Vuno is the first company to have three such designations to its name. “We developed Vuno Med DeepECG via long-term ECG data analysis research. With this breakthrough designation, we target expanding our market share in the medical AI industry via our bio-signal businesses. Among these is ECG data, which can help diagnose various heart diseases and has high potential,” Yeha Lee, chairman at Vuno, told BioWorld.
Exosomes from human induced pluripotent stem cell-derived cardiac cells have, for the first time, been conclusively shown to improve recovery from myocardial infarction in pigs, in a collaborative study begun 7 years ago by U.S. researchers.
While the disappearing drug-eluting stent seems to have faded from view for the time being, several manufacturers have invested in fabrication of drug-eluting stents with polymers that absorb once the drug of elution has done its work. A new study indicates that patients who have already had a myocardial infarction fare better on stents made with these biodegradable polymers, an outcome that may soon push second-generation DES devices into med-tech history.
A little less than a year after it reported the final close of a series D financing, Miracor Medical SA, of Awans, Belgium, has been granted breakthrough device designation by the U.S. FDA for its Pressure-Controlled Intermittent Coronary Sinus Occlusion (PICSO) Impulse System for the treatment of ST-elevated myocardial infarction (STEMI) patients.